

1. Sales January to December 2010 and 2009

	2010	2009	% change	
	CHF m	CHF m	In CHF	In local currencies
January – December				
Pharmaceuticals Division	37,058	38,996	-5	-2
United States	14,071	14,805	-5	-1
Western Europe	9,467	10,827	-13	-5
Japan	4,319	4,765	-9	-12
International	9,201	8,599	+7	+8
Diagnostics Division	10,415	10,055	+4	+8
Roche Group	47,473	49,051	-3	0

2. Quarterly local sales growth by Division in 2010

	Q1 2010 vs. Q1 2009	Q2 2010 vs. Q2 2009	Q3 2010 vs. Q3 2009	Q4 2010 vs. Q4 2009
Pharmaceuticals Division	+10	-2	-5	-8
United States	+10	-5	-1	-8
Western Europe	+4	-2	-11	-13
Japan	-9	-3	-22	-11
International	+25	+4	+5	-1
Diagnostics Division	+9	+9	+7	+6
Roche Group	+9	0	-3	-5

3. Quarterly sales by Division in 2009 and 2010

CHF millions	Q4 2009	Q1 2010	Q2 2010	Q3 2010	Q4 2010
Pharmaceuticals Division	9,962	9,727	9,659	9,009	8,663
United States	3,648	3,647	3,725	3,506	3,193
Western Europe	2,801	2,597	2,447	2,251	2,172
Japan	1,275	988	1,073	1,076	1,182
International	2,238	2,495	2,414	2,176	2,116
Diagnostics Division	2,690	2,518	2,732	2,482	2,683
Roche Group	12,652	12,245	12,391	11,491	11,346

4. Top 20 Pharmaceuticals Division product sales and local growth YTD December 2010 vs. YTD December 2009: US, Western Europe, Japan and International

	Total		United States		Western Europe		Japan		International	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Avastin	6,461	9%	3,190	0%	1,762	7%	625	51%	884	31%
MabThera/Rituxan	6,356	9%	3,026	4%	1,639	8%	273	9%	1,418	20%
Herceptin	5,429	7%	1,591	6%	2,075	6%	300	-15%	1,463	18%
Pegasys	1,645	2%	389	0%	352	-4%	124	-6%	780	9%
Lucentis	1,458	27%	1,458	27%	-	-	-	-	-	-
Xeloda	1,426	17%	530	17%	305	6%	128	62%	463	17%
Tarceva	1,325	6%	523	5%	432	-1%	94	37%	276	16%
CellCept	1,290	-15%	275	-48%	451	-2%	61	16%	503	5%
NeoRecormon/Epogin	1,285	-15%	-	-	474	-24%	476	-10%	335	-4%
Bonviva/Boniva	1,013	1%	526	-4%	293	5%	-	-	194	10%
Tamiflu	873	-73%	243	-72%	2	-100%	216	-76%	412	-37%
Xolair	641	8%	641	8%	-	-	-	-	-	-
Valcyte/Cymevene	605	12%	303	15%	169	11%	-	-	133	7%
Pulmozyme	513	6%	300	4%	109	-1%	-	-	104	25%
Activase/TNKase	460	4%	415	5%	-	-	-	-	45	-4%
Nutropin	405	5%	394	5%	-	-	-	-	11	-8%
Actemra/RoActemra	397	177%	58	-	136	235%	167	67%	36	653%
Xenical	337	-12%	27	-16%	151	-14%	-	-	159	-9%
Neutrogen	331	-16%	-	-	-	-	331	-16%	-	-
Rocephin	311	3%	1	-59%	57	-7%	64	-1%	189	10%

5. Top 20 Pharmaceuticals Division quarterly local product sales growth

	Q1 2010 vs. Q1 2009	Q2 2010 vs. Q2 2009	Q3 2010 vs. Q3 2009	Q4 2010 vs. Q4 2009
Avastin	18%	10%	7%	2%
MabThera/Rituxan	13%	6%	6%	10%
Herceptin	11%	5%	8%	5%
Pegasys	15%	-4%	-8%	9%
Lucentis	27%	27%	34%	20%
Xeloda	23%	16%	16%	14%
Tarceva	6%	10%	9%	0%
CellCept	-28%	-15%	-14%	5%
NeoRecormon/Epogin	-8%	-16%	-16%	-18%
Bonviva/Boniva	17%	0%	2%	-13%
Tamiflu	32%	-72%	-90%	-94%
Xolair	5%	10%	10%	5%
Valcyte/Cymevene	18%	4%	11%	14%
Pulmozyme	17%	0%	2%	5%
Activase/TNKase	-6%	15%	15%	-3%
Nutropin	-6%	-4%	19%	11%
Actemra/RoActemra	236%	175%	176%	158%
Xenical	-11%	-12%	-17%	-9%
Neutrogen	-5%	-16%	-23%	-18%
Rocephin	10%	-6%	8%	2%

6. Pharmaceuticals Division quarterly local product sales growth United States

	Q1 2010 vs. Q1 2009	Q2 2010 vs. Q2 2009	Q3 2010 vs. Q3 2009	Q4 2010 vs. Q4 2009
Avastin	13%	1%	-3%	-10%
MabThera/Rituxan	8%	2%	2%	6%
Herceptin	14%	0%	4%	7%
Pegasys	9%	0%	-12%	6%
Lucentis	27%	27%	34%	20%
Xeloda	25%	26%	8%	10%
Tarceva	2%	10%	13%	-6%
CellCept	-65%	-47%	-47%	40%
NeoRecormon/Epogin	-	-	-	-
Bonviva/Boniva	14%	-9%	2%	-21%
Tamiflu	1099%	-91%	-97%	-89%
Xolair	5%	10%	10%	5%
Valcyte/Cymevene	28%	2%	13%	18%
Pulmozyme	9%	5%	-1%	2%
Activase/TNKase	-5%	16%	16%	-3%
Nutropin	-6%	-4%	20%	11%
Actemra/RoActemra	-	-	-	-
Xenical	26%	-20%	-32%	-37%
Neutrogen	-	-	-	-
Rocephin	2325%	-62%	-	-

7. Pharmaceuticals Division quarterly local product sales growth Western Europe

	Q1 2010 vs. Q1 2009	Q2 2010 vs. Q2 2009	Q3 2010 vs. Q3 2009	Q4 2010 vs. Q4 2009
Avastin	18%	9%	4%	-3%
MabThera/Rituxan	14%	7%	5%	5%
Herceptin	12%	5%	4%	1%
Pegasys	-4%	-11%	-4%	2%
Lucentis	-	-	-	-
Xeloda	10%	6%	1%	7%
Tarceva	3%	5%	-8%	-5%
CellCept	5%	-2%	-2%	-7%
NeoRecormon/Epogin	-17%	-25%	-26%	-30%
Bonviva/Boniva	12%	9%	0%	-2%
Tamiflu	-97%	-	-100%	-
Xolair	-	-	-	-
Valcyte/Cymevene	19%	7%	10%	7%
Pulmozyme	5%	-8%	-1%	1%
Activase/TNKase	-	-	-	-
Nutropin	-	-	-	-
Actemra/RoActemra	1213%	317%	210%	114%
Xenical	5%	-14%	-24%	-23%
Neutrogen	-	-	-	-
Rocephin	-6%	-1%	0%	-18%

8. Pharmaceuticals Division quarterly local product sales growth Japan

	Q1 2010 vs. Q1 2009	Q2 2010 vs. Q2 2009	Q3 2010 vs. Q3 2009	Q4 2010 vs. Q4 2009
Avastin	53%	51%	51%	50%
MabThera/Rituxan	6%	5%	8%	16%
Herceptin	-14%	-20%	-15%	-10%
Pegasys	-12%	-13%	-4%	5%
Lucentis	-	-	-	-
Xeloda	81%	84%	64%	33%
Tarceva	19%	35%	45%	45%
CellCept	12%	15%	12%	25%
NeoRecormon/Epogin	-7%	-10%	-10%	-11%
Bonviva/Boniva	-	-	-	-
Tamiflu	-47%	-76%	-88%	-89%
Xolair	-	-	-	-
Valcyte/Cymevene	-	-	-	-
Pulmozyme	-	-	-	-
Activase/TNKase	-	-	-	-
Nutropin	-	-	-	-
Actemra/RoActemra	73%	62%	60%	74%
Xenical	-	-	-	-
Neutrogen	-5%	-16%	-23%	-18%
Rocephin	-13%	2%	-2%	6%

9. Pharmaceuticals Division quarterly local product sales growth International

	Q1 2010 vs. Q1 2009	Q2 2010 vs. Q2 2009	Q3 2010 vs. Q3 2009	Q4 2010 vs. Q4 2009
Avastin	25%	33%	34%	32%
MabThera/Rituxan	27%	14%	16%	25%
Herceptin	12%	20%	29%	13%
Pegasys	36%	-1%	-9%	16%
Lucentis	-	-	-	-
Xeloda	21%	2%	28%	21%
Tarceva	16%	11%	26%	10%
CellCept	5%	4%	8%	3%
NeoRecormon/Epogin	6%	-10%	-4%	-7%
Bonviva/Boniva	33%	11%	6%	-6%
Tamiflu	620%	-21%	-70%	-99%
Xolair	-	-	-	-
Valcyte/Cymevene	-1%	6%	8%	13%
Pulmozyme	78%	-3%	18%	22%
Activase/TNKase	-24%	3%	2%	5%
Nutropin	-3%	-7%	-16%	-5%
Actemra/RoActemra	1152%	861%	900%	458%
Xenical	-30%	-7%	-5%	12%
Neutrogen	-	-	-	-
Rocephin	20%	-9%	16%	18%

10. Top 20 Pharmaceuticals Division quarterly product sales

CHF millions	Q4 2009	Q1 2010	Q2 2010	Q3 2010	Q4 2010
Avastin	1,538	1,666	1,727	1,608	1,460
MabThera/Rituxan	1,481	1,606	1,695	1,520	1,535
Herceptin	1,294	1,417	1,389	1,357	1,266
Pegasys	375	441	428	384	392
Lucentis	329	327	370	384	377
Xeloda	308	352	380	361	333
Tarceva	342	326	348	331	320
CellCept	287	357	345	299	289
NeoRecormon/Epogin	380	339	338	312	296
Bonviva/Boniva	278	277	267	246	223
Tamiflu	1,196	517	193	98	65
Xolair	150	148	176	167	150
Valcyte/Cymevene	142	149	147	157	152
Pulmozyme	128	135	129	121	128
Activase/TNKase	122	110	117	119	114
Nutropin	89	91	102	117	95
Actemra/RoActemra	53	66	89	107	135
Xenical	90	91	92	76	78
Neutrogen	96	81	86	82	82
Rocephin	70	82	83	77	69

11. Pharmaceuticals Division quarterly product sales United States

CHF millions	Q4 2009	Q1 2010	Q2 2010	Q3 2010	Q4 2010
Avastin	771	845	887	802	656
MabThera/Rituxan	703	763	822	729	712
Herceptin	359	408	418	398	367
Pegasys	87	102	106	92	89
Lucentis	329	327	370	384	377
Xeloda	118	123	147	136	124
Tarceva	142	120	138	138	127
CellCept	34	83	76	62	54
NeoRecormon/Epogin	-	-	-	-	-
Bonviva/Boniva	148	144	140	132	110
Tamiflu	400	170	31	2	40
Xolair	150	148	176	167	150
Valcyte/Cymevene	66	70	73	86	74
Pulmozyme	77	75	76	73	76
Activase/TNKase	111	100	105	109	101
Nutropin	87	88	100	114	92
Actemra/RoActemra	-	5	9	18	26
Xenical	7	10	7	6	4
Neutrogen	-	-	-	-	-
Rocephin	2	2	1	-1	-1

12. Pharmaceuticals Division quarterly product sales Western Europe

CHF millions	Q4 2009	Q1 2010	Q2 2010	Q3 2010	Q4 2010
Avastin	458	484	462	423	393
MabThera/Rituxan	408	442	422	394	381
Herceptin	528	570	527	506	472
Pegasys	91	99	92	78	83
Lucentis	-	-	-	-	-
Xeloda	77	81	78	73	73
Tarceva	121	116	116	98	102
CellCept	125	123	117	108	103
NeoRecormon/Epogin	157	141	125	111	97
Bonviva/Boniva	81	79	76	68	70
Tamiflu	297	3	0	0	-1
Xolair	-	-	-	-	-
Valcyte/Cymevene	43	46	41	41	41
Pulmozyme	29	30	27	26	26
Activase/TNKase	-	-	-	-	-
Nutropin	-	-	-	-	-
Actemra/RoActemra	20	27	33	37	39
Xenical	44	44	43	34	30
Neutrogin	-	-	-	-	-
Rocephin	17	16	15	13	13

13. Pharmaceuticals Division quarterly product sales Japan

CHF millions	Q4 2009	Q1 2010	Q2 2010	Q3 2010	Q4 2010
Avastin	120	120	156	162	187
MabThera/Rituxan	67	53	69	70	81
Herceptin	88	67	77	74	82
Pegasys	33	26	31	31	36
Lucentis	-	-	-	-	-
Xeloda	25	27	33	33	35
Tarceva	19	17	24	24	29
CellCept	14	12	16	15	18
NeoRecormon/Epogin	138	102	123	123	128
Bonviva/Boniva	-	-	-	-	-
Tamiflu	233	126	16	46	28
Xolair	-	-	-	-	-
Valcyte/Cymevene	-	-	-	-	-
Pulmozyme	-	-	-	-	-
Activase/TNKase	-	-	-	-	-
Nutropin	-	-	-	-	-
Actemra/RoActemra	31	30	39	43	55
Xenical	-	-	-	-	-
Neutrogen	96	81	86	82	82
Rocephin	15	13	18	16	17

14. Pharmaceuticals Division quarterly product sales International

CHF millions	Q4 2009	Q1 2010	Q2 2010	Q3 2010	Q4 2010
Avastin	189	217	222	221	224
MabThera/Rituxan	303	348	382	327	361
Herceptin	319	372	367	379	345
Pegasys	164	214	199	183	184
Lucentis	-	-	-	-	-
Xeloda	88	121	122	119	101
Tarceva	60	73	70	71	62
CellCept	114	139	136	114	114
NeoRecormon/Epogin	85	96	90	78	71
Bonviva/Boniva	49	54	51	46	43
Tamiflu	266	218	146	50	-2
Xolair	-	-	-	-	-
Valcyte/Cymevene	33	33	33	30	37
Pulmozyme	22	30	26	22	26
Activase/TNKase	11	10	12	10	13
Nutropin	2	3	2	3	3
Actemra/RoActemra	2	4	8	9	15
Xenical	39	37	42	36	44
Neutrogen	-	-	-	-	-
Rocephin	36	51	49	49	40